Seasoned drug development teams from AmpliPhi Biosciences Corporation and C3J Therapeutics have joined together to form Armata Pharmaceuticals (NYSE American: ARMP) to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives. Please visit the LinkedIn page at: https://lnkd.in/ga-jvfg and the company website at: www.armatapharma.com
